dicentra, a world-renowned Contract Research Organization (CRO) and global consulting firm are proud to congratulate their client, Allerpops, who has completed enrolment on their phase II clinical trial on allergic rhinitis. The 72 healthy participants volunteered at dicentra's clinical research site in Toronto, Canada.
TORONTO, Ontario, Sept. 26, 2022 /PRNewswire-PRWeb/ -- dicentra, a world-renowned Contract Research Organization (CRO) and global consulting firm are proud to congratulate their client, Allerpops, for recently completing enrolment for their phase II clinical trial on allergic rhinitis. The 72 healthy participants volunteered at dicentra's clinical research site in Toronto, Canada.
dicentra's Toronto site allowed for fast recruitment of participants due to its downtown location being located on multiple transit routes, providing access to millions of potential participants within a 20-mile radius. dicentra prides itself on having the capacity to recruit participants quickly to meet the needs of clinical trial sponsors, offering a state-of-the-art clinical research clinic strategically located in the heart of Toronto, Canada.
According to the The American Academy of Allergy, Asthma & Immunology (AAAAI), allergic rhinitis, also known as nasal allergies, hay fever, or seasonal allergies, affects between 10% to 30% of the global population. Despite this high prevalence, the etiology and pathophysiology of allergic rhinitis are complex and many cases often go undiagnosed or misdiagnosed. Allergic rhinitis is characterized by a number of symptoms including sneezing, runny nose, itching, and nasal congestion.
This phase II trial marks the first clinical trial for AllerPops, a Los-Alamos-based company dedicated to relieving nasal allergies (allergic rhinitis). The trial, described as a randomized, double-blind, controlled, single-centre, 21-day study, received approval from Health Canada in March of 2022. The trial's objective is to assess the efficacy and safety of the investigational product AllerPops on nasal allergy symptoms.
"We want to congratulate AllerPops on pursuing this clinical trial and are proud to be a part of fast-tracking a truly innovative concept that intends to address people suffering from allergies," says Peter Wojewnik, Partner at dicentra. "We pride ourselves in our ability to meet the recruitment needs of all of our clinical trial sponsors, offering a state-of-the-art clinical research clinic strategically located in the heart of Toronto, Canada."
"It was very important to understand the sponsor's expectations and vision. Experts from multiple departments stepped in to brainstorm and strategize the most efficient regulatory pathway that will also meet the sponsor's long-term goals," says Priyanka Bhatt, Project Manager at dicentra. "The product is a breakthrough concept and we are very happy to be able to bring the Sponsor's vision to fruition! After all, this is what happens at dicentra, we accelerate innovation!"
"This trial was an important instrument to grow our business. I am glad to have had Dicentra conduct the clinical trial." Said Dr. Cliff Shunsheng Han, the founder of AllerPops, "Their expertise in trial design and government regulations allowed the trial creation process to pass much smoother than expected. Their experience and resources also guaranteed the timely completion of participant enrollment."
Results from this clinical trial are expected by October 21st, 2022.
About Allerpops
Allerpops Corp. is a Los Alamos-based company dedicated to relieving allergies for long periods, removing the need for daily shots or pills. The company's guiding principle is reconnecting customers with nature and the world. https://allerpops.com/
About dicentra
dicentra is a leading Contract Research Organization (CRO) and global consulting firm that specializes in addressing all matters related to safety, quality, and compliance for all product categories in the life sciences and food industries. We evaluate, implement, and provide all the necessary support for products and operations to gain market access and build confidence in your brand. We achieve this through our three business divisions: consulting, clinical trials, and certifications. Since our inception in 2002, we have completed over 24,000 projects and serviced over 1,400 companies internationally. https://dicentra.com/
Media Contact
Kory Punkkinen, dicentra, 416 - 361 - 3400, [email protected]
SOURCE dicentra
Share this article